Business
Issue of Equity and Director/PDMR Shareholding
Issue of Equity and Director/PDMR Shareholding.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 8365D N4 Pharma PLC 05 February 2018 \n\n05 February 2018\nN4 Pharma Plc\n(\"N4 Pharma\" or the \"Company\")\nIssue of Deferred Consideration Shares\n \nand\n \nDirector/PDMR Shareholding\n \n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to announce the issue of 4,591,400 new ordinary shares of 0.4p each (the \"Deferred Consideration Shares\") to Nigel Theobald, the Company's CEO, in accordance with the terms of the share purchase agreement entered into between the Company and Nigel Theobald dated 13 April 2017 (the \"Agreement\").\nUnder the terms of the Agreement, the Company (then called Onzima Ventures Plc) agreed to acquire the remaining issued share capital of N4 Pharma Limited from Nigel Theobald that it did not already own through the issue of 4,510,800 initial consideration shares (the \"Initial Consideration Shares\") with further deferred consideration payable, being the Deferred Consideration Shares, if, within two years from the date of Agreement, the Company's share price closed above 15p for a period of ten consecutive dealing days (such price being over a 100 per cent. premium to the price per share at which the Initial Consideration Shares were issued of 7p).\nThe Deferred Consideration Shares shall be subject to lock-in on the same terms as all other shares held by Nigel Theobald as detailed in the Company's admission document dated 13 April 2017. Following the issue of the Deferred Consideration Shares, Nigel Theobald will be interested in 16,846,633 ordinary shares representing 19.69 per cent. of the issued share capital of the Company as enlarged by the issue of the Deferred Consideration Shares.\nApplication has been made for admission of the Deferred Consideration Shares to trading on AIM (\"Admission\"). It is expected that Admission will take place and that dealings in the Deferred Consideration Shares will commence on AIM at 8.00 a.m. on 8 February 2018.\nFollowing Admission, there will be a total of 85,550,013 ordinary shares in issue. Shareholders should use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the FCA's Dis...